Conmed (CNMD) Tops Q1 EPS by 7c, provides guidance

Conmed (NYSE: CNMD) reported Q1 EPS of $0.89, $0.07 better than the analyst estimate of $0.82. Revenue for the quarter came in at $317 million versus the consensus estimate of $310.59 million.

GUIDANCE:

Conmed sees FY2026 EPS of $4.30-$4.45, versus the consensus of $4.35.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight
• Morgan Stanley Upgrades Sangfor Technologies Inc (300454:CH) to Overweight
• UBS Upgrades Celestica (CLS) to Buy